# OnCo record paper-cheng-adriatic-durvalumab-limited-stage-sclc-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-cheng-adriatic-durvalumab-limited-stage-sclc-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-cheng-adriatic-durvalumab-limited-stage-sclc-nejm-2024" ;
  schema:name "Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer"@en ;
  schema:description "ADRIATIC gave immunotherapy after chemoradiotherapy for limited-stage small-cell lung cancer and lifted median survival from 33.4 to 55.9 months, the largest gain the disease has seen."@en ;
  schema:url <https://onco.cc/key-papers/paper-cheng-adriatic-durvalumab-limited-stage-sclc-nejm-2024/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2404873>, <https://pubmed.ncbi.nlm.nih.gov/39268857/>, <https://clinicaltrials.gov/study/NCT03703297> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2404873> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Cheng Y, Spigel DR, Cho BC, et al." ;
  onco:related <https://onco.cc/key-papers/paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999/>, <https://onco.cc/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/>, <https://onco.cc/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/limited-stage-sclc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/radiation/> ;
  onco:technologies <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/tremelimumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:pathways <https://onco.cc/terms/immune-checkpoint/> ;
  onco:terms <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/prophylactic-cranial-irradiation/> ;
  onco:trials <https://onco.cc/trials/adriatic/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .